Compare WKHS & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WKHS | ELOX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3M | 41.0M |
| IPO Year | 2008 | 2013 |
| Metric | WKHS | ELOX |
|---|---|---|
| Price | $3.09 | $18.27 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | ★ 75.7K | 52.9K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.92 | 41.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $763,173.00 | N/A |
| Revenue This Year | $89.23 | N/A |
| Revenue Next Year | $28.84 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.53 | $10.00 |
| 52 Week High | $11.80 | $19.96 |
| Indicator | WKHS | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 65.51 |
| Support Level | $2.76 | $10.74 |
| Resistance Level | $3.50 | $19.36 |
| Average True Range (ATR) | 0.24 | 2.09 |
| MACD | 0.01 | 0.44 |
| Stochastic Oscillator | 49.50 | 83.42 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric vehicles, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.